Development and Evaluation of Self-Microemulsifying Drug Delivery System for Improving Oral Absorption of Poorly Water-Soluble Olaparib
暂无分享,去创建一个
Han‐Gon Choi | Jun-Pil Jee | K. Cho | Dong-Jin Jang | Sung Tae Kim | Thi-Thao-Linh Nguyen | Sung-Hoon Ahn | Seong-Bo Kim | Yong-Han Kim | E. Heo | Se-Hee Choi | Kyung-Sun Moon | Tae-Yong Sim | Hyun-Suk Jung
[1] R. Leblanc,et al. Polyethylene glycol (PEG) derived carbon dots: Preparation and applications , 2020 .
[2] I. Rabinowitch,et al. Oral Administration of Artemisone for the Treatment of Schistosomiasis: Formulation Challenges and In Vivo Efficacy , 2020, Pharmaceutics.
[3] B. Dong,et al. Advances and perspectives of PARP inhibitors , 2019, Experimental Hematology & Oncology.
[4] David J Brayden,et al. Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[5] Upendra Bulbake,et al. Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib , 2019, AAPS PharmSciTech.
[6] Weifeng Lin,et al. Poly-phosphocholinated Liposomes Form Stable Superlubrication Vectors. , 2019, Langmuir : the ACS journal of surfaces and colloids.
[7] Diansong Zhou,et al. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients , 2018, Clinical Pharmacokinetics.
[8] Shinn-Zong Lin,et al. A PEG-Based Hydrogel for Effective Wound Care Management , 2018, Cell transplantation.
[9] D. Hughes. Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib , 2017 .
[10] Thomas Lorenz,et al. Novel strategies for the formulation and processing of poorly water‐soluble drugs , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[11] R. Ghadi,et al. BCS class IV drugs: Highly notorious candidates for formulation development , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[12] C. Scott,et al. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum‐sensitive recurrent ovarian cancer , 2016, Asia-Pacific journal of clinical oncology.
[13] Jiangnan Yu,et al. Enhanced oral bioavailability of [6]-Gingerol-SMEDDS: Preparation, in vitro and in vivo evaluation , 2016 .
[14] T. Kojima,et al. A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[15] R. Plummer,et al. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib , 2016, Targeted Oncology.
[16] A. Bauer-Brandl,et al. Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying. , 2015, International journal of pharmaceutics.
[17] V. Jannin,et al. Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity. , 2015, International journal of pharmaceutics.
[18] Surjyanarayan Mandal,et al. Mucoadhesive microemulsion of ibuprofen: design and evaluation for brain targeting efficiency through intranasal route , 2015 .
[19] A. Joshi,et al. Self-microemulsifying drug delivery system (SMEDDS) – challenges and road ahead , 2015, Drug delivery.
[20] N. Udupa,et al. Role of Components in the Formation of Self-microemulsifying Drug Delivery Systems , 2015, Indian journal of pharmaceutical sciences.
[21] R. Jachowicz,et al. Preformulation Studies on Solid Self-Emulsifying Systems in Powder Form Containing Magnesium Aluminometasilicate as Porous Carrier , 2014, AAPS PharmSciTech.
[22] Prakash Khadka,et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability , 2014 .
[23] Sandeep Kalepu,et al. Oral lipid-based drug delivery systems – an overview , 2013 .
[24] Anette Müllertz,et al. Lipid-based formulations for oral administration of poorly water-soluble drugs. , 2013, International journal of pharmaceutics.
[25] Jaehwi Lee,et al. Liposomal formulations for enhanced lymphatic drug delivery , 2013 .
[26] Hywel D Williams,et al. Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.
[27] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[28] Koichi Wada,et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. , 2011, International journal of pharmaceutics.
[29] Z. A. Worku,et al. Oral formulation strategies to improve solubility of poorly water-soluble drugs , 2011, Expert opinion on drug delivery.
[30] A. Fahr,et al. Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage application. , 2011, International journal of pharmaceutics.
[31] D. Lindsay,et al. Effects of artemisinin and Artemisia extracts on Haemonchus contortus in gerbils (Meriones unguiculatus). , 2011, Veterinary parasitology.
[32] J. Benneyan,et al. Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[33] Gordon L. Amidon,et al. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs , 2009, The AAPS Journal.
[34] K. Sawant,et al. Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. , 2009, Current drug delivery.
[35] M. Singh,et al. Exemestane Loaded Self-Microemulsifying Drug Delivery System (SMEDDS): Development and Optimization , 2008, AAPS PharmSciTech.
[36] A. Narang,et al. Stable drug encapsulation in micelles and microemulsions. , 2007, International journal of pharmaceutics.
[37] A. Fahr,et al. Drug delivery strategies for poorly water-soluble drugs , 2007, Expert opinion on drug delivery.
[38] C. Pouton,et al. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[39] W. Charman,et al. Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .
[40] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[41] Pilar Ventosa-Andrés,et al. DRUG SOLUBILITY : IMPORTANCE AND ENHANCEMENT TECHNIQUES , 2016 .
[42] K. Anand,et al. Techniques for solubility enhancement of poorly soluble drugs: an overview , 2012 .
[43] V. Sharma,et al. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications : A recent review , 2012 .
[44] A. Chen,et al. PARP inhibitor treatment in ovarian and breast cancer. , 2011, Current problems in cancer.
[45] 賢一 大河原,et al. Self-microemulsifying drug delivery system (SMEDDS)製剤によるジゴキシンの吸収挙動改善 , 2010 .
[46] G. Powis. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. , 1983, Drug metabolism reviews.